Fibrate Therapy Guidelines

Primary Indications for Fibrate Therapy

The American Diabetes Association recommends fibrates as first-line therapy when triglycerides are ≥500 mg/dL to prevent acute pancreatitis, regardless of other lipid levels or cardiovascular risk 1, 2
For moderate hypertriglyceridemia (200-499 mg/dL), the American College of Cardiology suggests fibrates are second-line after statins have been optimized, particularly in patients with the metabolic syndrome pattern of high triglycerides (≥204 mg/dL) combined with low HDL cholesterol (≤34 mg/dL) 1, 2
The American Heart Association indicates that the specific subgroup most likely to benefit from fibrate therapy: patients with triglycerides ≥204 mg/dL AND HDL cholesterol ≤34 mg/dL, based on ACCORD trial subgroup analysis 1, 2

For HIV-infected patients on antiretroviral therapy with triglycerides exceeding 500 mg/dL, the Infectious Diseases Society of America recommends gemfibrozil or fenofibrate as initial therapy 3
For triglycerides 200-500 mg/dL with elevated non-HDL cholesterol in HIV patients, the Infectious Diseases Society of America suggests fibrates are an appropriate option alongside statins 3

The American College of Cardiology states that severe renal impairment (eGFR <30 mL/min/1.73 m²) or dialysis patients is an absolute contraindication for fenofibrate due to severe drug accumulation and rhabdomyolysis risk 4
The National Kidney Foundation recommends reducing fenofibrate to maximum 54 mg daily and monitoring renal function intensively for eGFR 30-59 mL/min/1.73 m² 2, 4
The American Heart Association advises against combining gemfibrozil with any statin due to markedly increased rhabdomyolysis risk 1, 4

The American Diabetes Association notes that fibrates have NOT been shown to reduce cardiovascular mortality or major adverse cardiovascular events in large randomized trials (FIELD, ACCORD) 1, 5
The American College of Cardiology indicates that the only consistent cardiovascular benefit from fibrate therapy: a 19% reduction in total cardiovascular events in the FIELD trial subgroup without pre-existing CVD, and potential benefit in ACCORD patients with triglycerides ≥204 mg/dL plus HDL ≤34 mg/dL 6, 5

The American Diabetes Association states that fenofibrate reduced diabetic retinopathy progression requiring laser treatment and slowed albuminuria progression in both FIELD and ACCORD trials 2, 5
The European Association for the Study of Diabetes suggests that this represents a unique benefit beyond lipid effects and may justify fenofibrate use in diabetic patients with hypertriglyceridemia and microvascular complications 2

The American College of Cardiology recommends starting fenofibrate immediately (54-160 mg daily with meals) for triglycerides ≥500 mg/dL, checking eGFR first 2
The National Lipid Association suggests optimizing statin therapy first if LDL is elevated or ASCVD risk ≥7.5% for triglycerides 200-499 mg/dL 2
The American Heart Association advises considering adding fenofibrate only if triglycerides remain >200 mg/dL after statin optimization AND patient has the high-risk pattern (triglycerides ≥204 mg/dL plus HDL ≤34 mg/dL) 1, 2

The American College of Cardiology recommends obtaining baseline liver enzymes (ALT, AST), renal function (creatinine, eGFR), and CPK before starting fenofibrate 2, 4
The National Kidney Foundation suggests rechecking renal function within 3 months, then every 6 months 2, 4
The American Heart Association advises monitoring liver enzymes periodically; discontinue if ALT/AST ≥3 times upper limit of normal persists 4

The American College of Cardiology states that fibrates should not be used as first-line therapy for LDL cholesterol reduction—statins are vastly superior with proven mortality benefit 2, 5
The American Heart Association advises against routinely combining statins with fibrates expecting cardiovascular benefit—combination therapy has not shown improved outcomes and increases myopathy risk 1, 2, 4